Can Testing Reports for Medical Device Registration in Indonesia Be Reused?

Clear answer: Testing reports originally prepared for NMPA, CE, FDA, ISO 13485, or other markets can sometimes be reused as part of an Indonesia medical device registration dossier, but they are not automatically accepted without review. Manufacturers should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation base, then assess the technical file, quality management system, labeling and instructions for use, local agent or authorized representative, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged timelines caused by unclear classification, missing evidence, or authorization arrangements.

Published: 2026-07-10 14:38 | Updated: 2026-07-10 14:38

Article Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Assessment Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI View
• Frequently Asked Follow-Up Questions
• Further Reading
• Applicability Boundaries

Key Summary

This FAQ addresses common questions in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance, with priority issues that companies need to assess in actual projects.

For Chinese medical device manufacturers, a more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Indonesia registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If the project is managed only by asking which documents must be submitted, corrections or rework can easily arise in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends placing this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

Source: Compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for whether medical device registration testing reports can be reused for Indonesia registration usually want to determine whether existing documents can support an Indonesia submission, whether a local agent or authorized representative is required, why timelines may be extended, and which issues may affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first make the core technical file, quality system evidence, performance verification, clinical evidence, and labeling and IFU into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact method, duration of use, sterility, whether active, and whether software or IVD attributes are involved, and then determine the risk class and submission pathway. If the pathway is misjudged, subsequent translation, notarization, authorization, testing, and supplementary documents will deviate from the correct direction.

For an Indonesia project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, testing report model coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

• Translating NMPA documents directly and submitting them without reorganizing the evidence according to the Indonesia pathway.
• Having too many model specifications while testing reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent only on the basis of sales cooperation without clarifying regulatory responsibility, certificate control, and post-market maintenance duties.
• Inconsistency among labels, IFU, promotional materials, and registration dossier claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and increased cost and timelines.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation base and avoid discovering critical evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, testing reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what must be retested, translated, notarized, or supported by additional declarations.

AIMEILI View

AIMEILI recommends that companies not treat Indonesia registration as a one-time document submission but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents separately for each country at short notice.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance, even if the documentation appears substantial.

Frequently Asked Follow-Up Questions

Can domestic documents be used directly for Indonesia registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to judge whether the project will affect launch plans.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labeling and IFU, clinical evaluation, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the registered product, or if the manufacturing address, model specifications, IFU version, and testing reports are inconsistent, the company may be required to provide supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, testing report numbers, clinical evaluation conclusions, risk management version, labeling and IFU version, and quality system certificate item by item. This action appears basic but can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Indonesia registration projects usually involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining approval but neglect post-market maintenance. Once a manufacturing address change, model expansion, IFU update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify target market priorities, then build a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country but also helping the company develop a replicable compliance capability for going global, reducing the cost of starting from zero each time it enters a new market.

Further Reading

Previous: How Should Clinical Evaluation Documents Be Prepared for Medical Device Registration in Indonesia?

Next: How Should an ISO 13485 Certificate Be Used for Medical Device Registration in Indonesia?

Recommended reading:

• How Should Registration Documents Be Prepared for Medical Device Registration in Malaysia?
• How Should Product Classification Be Determined for Medical Device Registration in Malaysia?
• How Should Technical Files Be Organized for Medical Device Registration in Malaysia?
• How Should Labels and IFU Be Localized for Medical Device Registration in Malaysia?
• How Should Clinical Evaluation Documents Be Prepared for Medical Device Registration in Malaysia?
• Can Testing Reports Be Reused for Medical Device Registration in Malaysia?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.